Investors benefit from our depth of coverage in healthcare and technologyContact Us
Our perspective is driven by significant Wall Street and investment analysis experience, combined with the industry and management consulting backgrounds that many of our research professionals possess. In addition, with respective to healthcare, we derive critical insights from SVB MEDACorp – a network of 20,000+ key opinion leaders and industry practitioners.
In Healthcare, we cover companies spanning Biotechnology; Digital Health; Healthcare Services; Lifescience Tools and Diagnostics; and Medical Supplies and Devices.
In Technology, our coverage of companies includes the following sub-sectors: Enterprise Software; Consumer Internet, Commerce Enablement & Marketing Software; Educational Technology; Digital Infrastructure & Tech-Enabled Services; Industrial Technology; and FinTech.
Healthcare Technology & Distribution / 2022 Digital Health: Innovators & Disruptors Conference Takeaways
Biopharma / Watchful Waiting: Amyloid Hypothesis at Stake with the Upcoming AD Readouts
Biopharma — Flash / Pricing Policy Call Takeaways & Updates to Exposure Analysis
Jackson Ader, CFA
Managing Director, Software
Jackson Ader, CFA, is a Research Analyst at SVB MoffettNathanson, covering the Software sector.
Prior to joining the firm in 2022, Jackson spent 10 years at J.P. Morgan where he was most recently a Senior Analyst and Executive Director in Equity Research covering Application Software.
He earned a B.S. in Business from Murray State University, a Masters in Finance from London Business School, and is a CFA Charterholder.
Sterling Auty, CFA
Senior Managing Director, Software
Sterling Auty, CFA, is a Senior Research Analyst at SVB MoffettNathanson, covering the Software sector.
Sterling joins us from J.P. Morgan with more than 25 years of experience covering software across all segments and sizes of companies. His holistic view of the software industry, combined with rich experience covering the sector, has led to insightful cyclical reports around valuation, impact of interest rates, and changes in demand across the sub-sectors of the industry.
In 2021, Sterling was voted #1 in the Small and Mid Cap Software sector of Institutional Investor Magazine’s All-American Research Team.
He earned a B.S. from the University of Tampa, an MBA from the University of Albany, and is a CFA Charterholder.
Andrew Berens, M.D.
Senior Managing Director, Targeted Oncology
Andrew Berens, M.D., is a Senior Research Analyst at SVB Securities covering Targeted Oncology.
Prior to joining the firm in 2018, Andrew was an Executive Director and Senior Biotechnology Research Analyst at Morgan Stanley focusing on mid- and small-cap biotechnology companies. He practiced as an emergency medicine physician for a decade before starting his career in equity research. He also worked in the pharma industry at Ikaria Pharmaceuticals, where he was a Senior Director in business development, leading search and development efforts.
In 2017 he was named a Runner Up in Institutional Investor’s 2017 All–America Research Team for Biotechnology/Mid- & Small-Cap.
He earned M.B.A. degrees from Columbia Business School and London Business School, his M.D. from Emory University, and an undergraduate degree in English Literature from Tulane University.
Jonathan Chang, Ph.D., CFA
Senior Managing Director, Emerging Oncology
Jonathan Chang, Ph.D., CFA is a Senior Research Analyst at SVB Securities covering Emerging Oncology. He has been an important contributor to the firm’s biotechnology research product and insights.
Jonathan joined the firm in 2013 as an Associate supporting the firm’s senior oncology biotechnology research team and in 2016, he assumed research coverage of several important emerging biotechnology companies. In 2018, he was named a Rising Star in Institutional Investor’s 2018 All-America Research Team for Biotechnology/Mid- & Small-Cap.
He earned a Ph.D. in Pharmacology from Cornell University, an M.A. in Biotechnology from Columbia University, and an Honors B.Sc. in Genes, Genetics, and Biotechnology from the University of Toronto. Dr. Chang is a CFA charter holder.
Senior Managing Director, Healthcare Technology and Distribution
Stephanie Davis, CFA, is a Senior Research Analyst at SVB Securities covering Healthcare Technology and Distribution. She has over a decade of experience covering the Healthcare IT and IT Services sectors and leads the firm’s digital health research efforts.
Prior to joining the firm, Stephanie worked at Citibank, where she led coverage for the Healthcare IT sector, including the electronic health record companies, payer-facing and provider-facing IT players. Before Citi, she was an Equity Research Analyst at J.P. Morgan and, earlier in her career, was an Investment Banking Analyst at Sonenshine Partners.
In 2019, Stephanie was recognized as a Runner-Up for Health Care Technology and Distribution on Institutional Investor’s All America Research Team and was included in Business Insider’s “Rising Stars of Equity Research” in 2017.
She earned a B.A. in Economics and Mathematics from Columbia University and is a CFA charter holder.
Nick Del Deo, CFA
Managing Director, Telecom and Communications Infrastructure
Nick Del Deo, CFA, is a Research Analyst at SVB MoffettNathanson, covering U.S. Telecom and Communications Infrastructure.
Prior to joining MoffettNathanson in 2013, Nick was a Vice President at Sanford C. Bernstein & Co., LLC covering U.S. Telecommunications and U.S. Cable & Satellite. Prior to joining Bernstein, Nick was a Senior Associate at Morgan Stanley Investment Management. He also worked at a start-up hedge fund and was briefly an auditor at Arthur Andersen.
In 2015, 2016, & 2017, Nick was named a Rising Star of Wall Street Research by Institutional Investor magazine.
He earned a B.S. in Economics with concentrations in Finance and Accounting and a B.A. in Economics from the University of Pennsylvania, and is a CFA Charterholder.
Senior Managing Director, Payments, Processors, and IT Services
Lisa Ellis is a Senior Research Analyst at SVB MoffettNathanson, and leads the Payments, Processors, and IT Services business.
Prior to joining the firm, Lisa was most recently a Managing Director and Senior Research Analyst at Sanford Bernstein & Co., LLC where she was the #1 Institutional Investor ranked Payments, Processors, and IT Services analyst. Prior to Bernstein, she spent thirteen years at McKinsey & Co. where she was a Partner in the firm’s Technology & Telecom and Marketing & Sales consulting practices. While at McKinsey, Lisa was the lead partner on dozens of engagements focused in strategic areas including specialty networks, mobile applications, cloud, and outsourcing.
In 2020, Lisa was selected to Barron’s list of “100 Most Influential Women in U.S. Finance”.
She earned a B.S. in Physics and Mathematics from the College of William & Mary where she graduated magna cum laude and Phi Beta Kappa. She also holds an M.S. in Materials Science & Engineering and an MBA, both from the University of Virginia.
Robert Fishman, CFA
Managing Director, Media and Internet
Robert Fishman, CFA, is a Research Analyst at SVB MoffettNathanson, covering the U.S. Media and Internet sectors and is the lead analyst on U.S. media networks, online gaming and theaters.
Prior to joining the firm at its inception in 2013, Robert was previously a Vice President at Nomura Securities, joining the firm in 2010 to cover the Media sector with Michael. Prior to Nomura, Robert was a Senior Associate at Bank of America Merrill Lynch covering the same industry group.
He earned a Bachelor of Commerce in Finance from McGill University and is a CFA Charterholder.
Mani Foroohar, M.D.
Senior Managing Director, Genetic Medicines
Mani Foroohar, M.D., is a Senior Research Analyst within our Therapeutics team focusing on Genetic Medicines.
Mani joined SVB Securities from Aptigon Capital, a Citadel Company, where he most recently was a Therapeutics Analyst focused on U.S. and EU biotechnology, major pharmaceuticals and specialty pharmaceuticals sectors. Prior to Aptigon, he was an Analyst at Green Owl Capital Management and an Assistant Vice President of Equity Research at Barclays. In 2013, Mani co-founded Cellanyx Diagnostics, a company developing a proprietary live tumor cell, phenotypic platform for precision risk stratification in cancer to inform clinical treatment decision-making.
He holds an M.D. from Stanford, where he was a Howard Hughes Medical Institute Research Fellow in the Department of Genetics, an M.B.A. from Columbia, and a B.S. from UCLA.
Senior Managing Director, Neuroscience
Marc Goodman is a Senior Research Analyst at SVB Securities covering Neuroscience and Ophthalmology.
Prior to joining the firm in 2018, Marc was most recently a Managing Director and U.S. Healthcare Analyst at UBS Investment Bank, where he focused on large-cap and specialty pharmaceuticals sectors. Prior to UBS, he covered specialty pharmaceuticals and generics sectors for over 15 years as a Managing Director at Crédit Suisse AG and as an Executive Director at Morgan Stanley.
Marc has been ranked by Institutional Investor as a top analyst in Specialty Pharmaceuticals for well over a decade and has also expanded his coverage and interests into global and emerging biopharmaceutical companies in recent years.
He earned his MBA from The Ohio State University and his B.A. in Economics from Tufts University.
Daina Graybosch, Ph.D.
Senior Managing Director, Immuno-Oncology
Daina Graybosch, Ph.D., is a Senior Research Analyst at SVB Securities covering Immuno-Oncology.
Prior to joining the firm in 2018, Daina worked at McKinsey & Company as a Senior Expert and Head of McKinsey’s Center for Asset Optimization, as well as the U.S. Head of the McKinsey Cancer Center. In these roles, she developed several McKinsey solutions that bring data and advanced analytics to pharmaceutical development decisions. In her 11 years at McKinsey, she developed a rich understanding of oncology through her work with companies across the value chain, including Pharmaceutical, Diagnostic, Academic Medical Center, and Genomic/Data.
She earned a Ph.D. in Chemistry and Chemical Biology from Harvard University and dual B.S. degrees in Biology and Chemistry from the University of Utah.
Senior Managing Director, Healthcare Providers & Managed Care
Whit Mayo is a Senior Managing Director and Senior Research Analyst covering Healthcare Providers & Managed Care at SVB Securities. He leads SVB Securities’ research across payors, providers, and health systems and provides strategic guidance and insight for our clients and partners.
Whit joined the firm in 2021 from UBS, where he most recently served as Managing Director. Prior to that, Whit covered the sector at Baird and Stephens, Inc.
In 2020 he was ranked in Institutional Investor’s All-America Research Team within the Health Care Facilities & Managed Care category.
He earned his Bachelor of Arts in Economics at Sewanee, The University of the South.
Senior Managing Director, Cable and Telecommunications
Craig Moffett has covered the Cable and Telecommunications industry – first as a management consultant and later as a Wall Street analyst – for more than thirty years. He has been elected to Institutional Investor Magazine’s All-American Research Team in the U.S. Telecom and/or Cable & Satellite sectors on seventeen separate occasions, including nine separate appearances as the #1 analyst in America in either U.S. Telecom and/or Cable & Satellite.
Prior to founding MoffettNathanson, Mr. Moffett spent more than ten years at Sanford Bernstein & Co., LLC as a senior research analyst. He was previously the President and founder of the e-commerce business at Sotheby’s Holdings, the venerable auction house, where, in 1999, he led Sothebys.com to what was then the highest first year sales of any consumer website ever launched. Mr. Moffett spent more than eleven years at The Boston Consulting Group, where he was a Partner and Vice President specializing in telecommunications. He was the leader of BCG’s global Telecommunications practice from 1996 to 1999. While at BCG, he led client initiatives in the U.S. local, long distance, and wireless sectors, in both consumer and commercial services, and advised companies outside the U.S. in Europe, Latin America, and Asia.
Mr. Moffett graduated from Harvard Business School with Honors in 1989. He received a BA from Brown University, where he was magna cum laude and Phi Beta Kappa, in 1984.
Michael Morton, CFA
Managing Director, Ecommerce and Internet Marketplaces
Michael Morton, CFA, is a Research Analyst at SVB MoffettNathanson, covering Ecommerce and Internet Marketplace sectors.
Prior to joining the firm in 2022, Michael joined from YouTube, where he worked in Strategy on the Market and Competitive Intelligence team. In his role, he worked to identify emerging trends in the consumer internet landscape. In addition, Michael brings over a decade of equity research experience, having previously served as a Director and Sector Specialist in Internet, Media, and Telecom at Sanford C. Bernstein & Co., LLC. Before that, he was a Research Analyst at Haverford Trust Company and Alara Capital Partners.
He earned a B.A. in Economics and Political Science from Pennsylvania State University and is a CFA Charterholder.
David Risinger, CFA
Senior Managing Director, Biopharma
David Risinger, CFA is a Senior Managing Director and Senior Research Analyst at SVB Securities covering Diversified Biopharmaceuticals.
Prior to joining the firm in 2022, David’s most recent Wall Street role was Head of US Major and Specialty Pharmaceuticals Equity Research for Morgan Stanley & Co. Prior to Morgan Stanley, he was head of Global Healthcare Research and Senior US Pharmaceutical analyst at Merrill Lynch & Co. He started his Wall Street career at Dillon, Read & Co. He has been a top-ranked analyst by Institutional Investor for decades, including achieving Runner-Up rankings in both Major Pharmaceuticals and Specialty Pharmaceuticals in 2021.
He earned his Bachelor of Arts in Political Science from Bucknell University and holds the Chartered Financial Analyst designation.
Roanna Ruiz, Ph.D.
Director, Infectious Disease, Endocrine & Cardiovascular Disorders
Roanna Ruiz, Ph.D., is a Senior Research Analyst at SVB Securities covering Infectious Disease, Endocrine and Cardiovascular Disorders (IDECV). She excels in quality of research, depth of insights and understanding, and the service provided to the firm’s internal and external clients. Prior to covering the IDECV sectors, she was a core member of SVB Securities’ Neuroscience team helping to deliver science-forward and deep-dive fundamental research to clients.
Roanna joined the firm in 2018 after holding equity research roles at UBS and H.C. Wainwright. Previously, Roanna spent two years in pharmaceutical industry consulting at IQVIA working on M&A, product launch strategy, and pricing & reimbursement projects.
She earned a Ph.D. in Biomedical Engineering from Cornell University, and a B.S. in Engineering Sciences from Harvard University.
Joseph P. Schwartz
Senior Managing Director, Rare Diseases
Joseph Schwartz is a Senior Research Analyst at SVB Securities covering Rare Diseases.
Prior to joining the firm in 2003, Joseph provided economic and strategic consulting services to biotechnology and pharmaceutical companies with Charles River Associates. Earlier in his career, he held equity research positions at SG Cowen, State Street Research, and J.P. Morgan, where he analyzed the fundamental performance drivers of investments in the health care, retail, consumer, media, and entertainment sectors.
He was named #1 Stock Picker for Pharmaceuticals in the 2011 FT/StarMine Analyst Awards. In 2010, he earned the Wall Street Journal’s #1 ranking for biotech stock picking as part of its “Best on the Street” analysts survey, which topped his #2 ranking in the Journal’s 2008 “Best on the Street” rankings.
He earned an M.B.A. from Babson College and a B.A. in Economics from Colby College.
Managing Director, Fintech and HR Services
Eugene Simuni is a Research Analyst at SVB MoffettNathanson, covering the Fintech and HR Services sectors.
Prior to joining the firm, Eugene was a member of the Corporate Strategy Group at JPMorgan Chase where he supported members of the bank’s Operating Committee on initiatives related to Payments strategy and other topics. Prior to JPMorgan, he led investment and technology initiatives at Bridgewater Associates. Eugene began his career at McKinsey & Company, where he was a member of the Corporate Finance practice and worked with financial services and technology clients.
He earned a B.A. in Applied Mathematics and Economics from Harvard and an MBA from the Wharton School of Business.
Thomas J. Smith
Senior Managing Director, Immunology and Metabolism
Thomas J. Smith is a Senior Research Analyst at SVB Securities covering Immunology and Metabolism. Prior to covering the Immunology and Metabolism sector, Thomas was a key member of SVB Securities’ Targeted Oncology team helping to deliver in-depth fundamental research to clients.
Prior to joining the firm in 2018, Thomas was most recently a Vice President and Research Analyst at Morgan Stanley, covering leading and emerging biopharmaceutical companies across numerous therapeutic areas, including oncology, NASH, and lead coverage of women’s health companies. Prior to that, he worked at FBR Capital Markets on the biotechnology team, responsible for coverage of large, mid- and small-cap companies. Thomas began his career at Bloomberg, where he held roles of increasing responsibility, including coverage of the biotech and specialty pharmaceutical sectors for Bloomberg Intelligence.
He earned his B.S. in Finance and Psychology from The College of New Jersey.
Senior Managing Director, Life Science Tools and Diagnostics
Puneet Souda is a Senior Research Analyst at SVB Securities covering Life Science Tools and Diagnostics. His research focuses on companies and technologies within the Life Science Tools subsector, the Diagnostics subsector, and selected areas of Pharmaceutical Services.
Prior to joining the firm in 2014, Puneet was a Senior Associate at Citigroup covering Medical Devices. Before joining Wall Street, he spent over a decade in core and basic research labs at UCLA and Purdue University. In this work, he was a customer and collaborator of many Life Science Tools and Diagnostic companies. Puneet has direct experience in the acquisition, management, and utilization of many life sciences technologies for molecular analysis and diagnostics. He has co-authored over 45 peer-reviewed scientific papers and has built an extensive network of colleagues and collaborators among academic lab researchers and Life Science Tools suppliers.
He earned an M.B.A. from University of California-San Diego and undertook graduate study in biotechnology and earned a B.A. in Biology from Purdue University.
Senior Managing Director, Director of Research
Jim Kelly is a Senior Managing Director, Director of Research at SVB Securities. Mr. Kelly is responsible for product management, analyst development and equity strategy.
Prior to joining SVB Securities in 2015, Mr. Kelly worked at Credit Suisse, where he served in research management as an Associate Director of Equity Research in New York and was responsible for leading key, strategic initiatives in research product and process development. Prior to his ADOR role at Credit Suisse, Mr. Kelly spent 13 years in Equity Research covering the US Pharmaceuticals industry for Lehman Brothers, Goldman Sachs and Credit Suisse First Boston.
Mr. Kelly received his M.B.A. from Columbia Business School and earned his B.S. in Mechanical Engineering from Lehigh University. Mr. Kelly also serves on the board of the Lehigh Business School Dean’s Advisory Council.
Managing Director, Associate Director of Research
Julia Belladonna is a Managing Director, Associate Director of Research at SVB Securities.
Julia joined the firm in 2021 from Credit Suisse where she spent 20+ years in a variety of roles, most recently as the COO of Global Economics for their Institutional client & Private Wealth Management businesses. She brings over two decades of experience in financial markets, business and talent management, international regulatory requirements, and operations. She has excelled in managing complex groups, collaborating across business units, and developing strategies to deliver research to clients. Prior to Credit Suisse, she was an Industry Analyst at Merrill Lynch.
Julia earned a B.A. in Applied Mathematics and History from Williams College and an M.B.A. in Finance from Columbia Business School.